Sign In
NewsRadar

AM-Pharma BV

AM-Pharma is a biopharmaceutical company focused on the discovery, development and commercialisation of novel therapeutics, derived from the innate human immune system, which can be used to treat a range of infectious and inflammatory diseases.

• Show past press releases
• Edit this company

Contact Information
Address:
 
 
Phone:
Fax:
Web:
Contact:
 
 
Rumpsterweg 6
Bunnik 3981 AK
Netherlands
+31 (0)30 228 92 22
+31 (0)30 228 92 20
http://www.am-pharma.com
Bart Wuurman
+31 (0)30 2289222

Company Facts
Founded:Jul 2002
Founders:
CEO:Erik van den Berg
CTO or technical lead:
CFO or finance director:Peter Verwaijen
Head of Sales:
Head of Marketing:

Stage:
Category:Biotechnology & Healthcare
Sector:Biopharmaceuticals
Employees:9
Profitability:
Funding raised:Yes
Funding sought:
Seeking Partnerships:

Non-executive Board Members

Key Customers

Key Business Partners

Key Competitors

Capital Raised
DateSizeInvestors
To view this information you must be signed in and subscribed to the online dataservice, sign in here.

To read more about the Online data service click here

Public Offerings
DateTypeExchange
No public offerings


Data


27,242
Tech investments
From our Online Data Service
17,580
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Jul 31€2.8MInternet services
Jul 30€9.5MWireless applications
Jul 30€4.5MSensors
Jul 30€5.0ME-Commerce
Jul 30N/ANetwork management
Jul 30€72.0MInternet services

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0





About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.